Onyx Bridge Wealth Group LLC Acquires 78 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 21st, 2023

Onyx Bridge Wealth Group LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,179 shares of the company’s stock after purchasing an additional 78 shares during the quarter. Onyx Bridge Wealth Group LLC’s holdings in Johnson & Johnson were worth $393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Lincoln Capital Corp raised its position in shares of Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares in the last quarter. Ieq Capital LLC raised its position in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC raised its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares in the last quarter. FDx Advisors Inc. raised its position in shares of Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after buying an additional 153 shares in the last quarter. Finally, HM Payson & Co. raised its position in shares of Johnson & Johnson by 3.2% during the 3rd quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock valued at $127,999,000 after buying an additional 24,188 shares in the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.0 %

Shares of NYSE JNJ opened at $153.89 on Tuesday. Johnson & Johnson has a 1 year low of $150.71 and a 1 year high of $186.69. The stock has a market cap of $400.77 billion, a P/E ratio of 22.83, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. The firm has a 50-day moving average of $161.53 and a 200 day moving average of $167.88. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the company posted $2.13 EPS. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.94%. Johnson & Johnson’s payout ratio is 67.06%.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $174.73.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.